Literature DB >> 28070994

Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells.

Zhong-Dong Wang1, Fan-Yong Qu2, Yuan-Yuan Chen3, Zhang-Shen Ran3, Hai-Yan Liu4, Hai-Dong Zhang5.   

Abstract

OBJECTIVE: Hepatocellular carcinoma (HCC) is still one of the most common death-related malignancies worldwide. Because the way onset and progression are hidden most, HCC diagnoses are made at an advanced stage, when they are unsuitable for surgical resection. MicroRNAs are a class of small non-coding RNAs, participating in many aspects of cancers. In this study, we tried to establish the role of microRNA-718 (miR-718) in the malignant phenotype of HCC cells and its possible role in HCC diagnosis.
METHODS: Here we first used a methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, Transwell migration and invasion assays, and colony formation assay to evaluate the impact of miR-718 on the malignant phenotypes of HCC cells. Then, we used bioinformatic methods to predict the target gene of miR-718 and used green fluorescence protein (GFP) reporter assay, Western blot, and quantitative real-time polymerase chain reaction (qRT-PCR) to validate the regulation relationship. Finally, we determined the role of the target gene in the HCC phenotype.
RESULTS: We found that the expression of miR-718 was significantly reduced in various HCC cell lines and HCC tissues. Re-expression of miR-718 significantly reduced the cellular viability and colony formation ability as well as inhibited the migration and invasion abilities of HCC cell lines. Early growth response protein 3 (EGR3) is a direct target of miR-718 and is negatively regulated by miR-718. EGR3 could increase the viability and proliferation of HCC cells, and promot the migration and invasion of HCC cells.
CONCLUSIONS: miR-718 acts as a tumor suppressive microRNA in HCC via regulating the expression of EGR3, which may provide a new diagnostic marker and treatment target for HCC.

Entities:  

Keywords:  miR-718; MicroRNA; Early growth response protein 3 (EGR3); Hepatocellular carcinoma (HCC); Malignant phenotype

Mesh:

Substances:

Year:  2017        PMID: 28070994      PMCID: PMC5260475          DOI: 10.1631/jzus.B1600205

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  23 in total

Review 1.  HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma.

Authors:  Fabrizio Bronte; Giuseppe Bronte; Daniele Fanale; Stefano Caruso; Enrico Bronte; Maria Grazia Bavetta; Eugenio Fiorentino; Christian Rolfo; Viviana Bazan; Vito Di Marco; Antonio Russo
Journal:  Crit Rev Oncol Hematol       Date:  2015-10-09       Impact factor: 6.312

2.  MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions.

Authors:  Girish C Shukla; Jagjit Singh; Sailen Barik
Journal:  Mol Cell Pharmacol       Date:  2011

3.  Egr3, a synaptic activity regulated transcription factor that is essential for learning and memory.

Authors:  Lin Li; Sung Hwan Yun; James Keblesh; Barbara L Trommer; Huangui Xiong; Jelena Radulovic; Warren G Tourtellotte
Journal:  Mol Cell Neurosci       Date:  2007-02-12       Impact factor: 4.314

4.  MiR-718 represses VEGF and inhibits ovarian cancer cell progression.

Authors:  Ruobing Leng; Lang Zha; Liangdan Tang
Journal:  FEBS Lett       Date:  2014-05-08       Impact factor: 4.124

Review 5.  Hepatocellular carcinoma: A comprehensive review.

Authors:  Lisa P Waller; Vrushak Deshpande; Nikolaos Pyrsopoulos
Journal:  World J Hepatol       Date:  2015-11-18

6.  Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor.

Authors:  Takashi Suzuki; Akio Inoue; Yasuhiro Miki; Takuya Moriya; Jun-ichi Akahira; Takanori Ishida; Hisashi Hirakawa; Yuri Yamaguchi; Shin-ichi Hayashi; Hironobu Sasano
Journal:  Endocr Relat Cancer       Date:  2007-06       Impact factor: 5.678

Review 7.  Early growth response transcription factors and the modulation of immune response: implications towards autoimmunity.

Authors:  Diana Gómez-Martín; Mariana Díaz-Zamudio; Miguel Galindo-Campos; Jorge Alcocer-Varela
Journal:  Autoimmun Rev       Date:  2009-12-23       Impact factor: 9.754

8.  Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation.

Authors:  K Sugimachi; T Matsumura; H Hirata; R Uchi; M Ueda; H Ueo; Y Shinden; T Iguchi; H Eguchi; K Shirabe; T Ochiya; Y Maehara; K Mimori
Journal:  Br J Cancer       Date:  2015-01-13       Impact factor: 7.640

9.  Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer.

Authors:  V T Baron; R Pio; Z Jia; D Mercola
Journal:  Br J Cancer       Date:  2015-01-29       Impact factor: 7.640

10.  Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer.

Authors:  Rebecca Pio; Zhenyu Jia; Veronique T Baron; Dan Mercola
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more
  12 in total

1.  A novel oncolytic adenovirus inhibits hepatocellular carcinoma growth.

Authors:  Yu-Huan Bai; Xiao-Jing Yun; Yan Xue; Ting Zhou; Xin Sun; Yan-Jing Gao
Journal:  J Zhejiang Univ Sci B       Date:  2019 Dec.       Impact factor: 3.066

2.  Expression profiling of microRNAs in human bone tissue from postmenopausal women.

Authors:  Laura De-Ugarte; Jenny Serra-Vinardell; Lara Nonell; Susana Balcells; Magdalena Arnal; Xavier Nogues; Leonardo Mellibovsky; Daniel Grinberg; Adolfo Diez-Perez; Natalia Garcia-Giralt
Journal:  Hum Cell       Date:  2017-09-20       Impact factor: 4.174

3.  Integrated analysis of hypoxia-induced miR-210 signature as a potential prognostic biomarker of hepatocellular carcinoma: a study based on The Cancer Genome Atlas.

Authors:  Yi Dai; Ji-Liang Shen; Xue-Yong Zheng; Tian-Yu Lin; Hai-Tao Yu
Journal:  J Zhejiang Univ Sci B       Date:  2019 Nov.       Impact factor: 3.066

4.  Identification of Key Differentially Expressed Transcription Factors in Glioblastoma.

Authors:  Gang Qin; Beiquan Hu; Xianfeng Li; Rongjie Li; Youshi Meng; Yimei Wang; Donghua Zou; Feng Wei
Journal:  J Oncol       Date:  2020-06-15       Impact factor: 4.375

Review 5.  An Update on Novel Therapeutic Warfronts of Extracellular Vesicles (EVs) in Cancer Treatment: Where We Are Standing Right Now and Where to Go in the Future.

Authors:  Muhammad Babar Khawar; Muddasir Hassan Abbasi; Zerwa Siddique; Amin Arif; Nadeem Sheikh
Journal:  Oxid Med Cell Longev       Date:  2019-07-25       Impact factor: 6.543

6.  LINC00680 and TTN-AS1 Stabilized by EIF4A3 Promoted Malignant Biological Behaviors of Glioblastoma Cells.

Authors:  Wei Tang; Di Wang; Lianqi Shao; Xiaobai Liu; Jian Zheng; Yixue Xue; Xuelei Ruan; Chunqing Yang; Libo Liu; Jun Ma; Zhen Li; Yunhui Liu
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-16       Impact factor: 8.886

7.  XIST promotes apoptosis and the inflammatory response in CSE-stimulated cells via the miR-200c-3p/EGR3 axis.

Authors:  Panfeng Chen; Ping Jiang; Jianing Chen; Yang Yang; Xiumei Guo
Journal:  BMC Pulm Med       Date:  2021-07-09       Impact factor: 3.317

8.  Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas.

Authors:  Arnon Møldrup Knudsen; Ida Eilertsen; Susanne Kielland; Mikkel Warming Pedersen; Mia Dahl Sørensen; Rikke Hedegaard Dahlrot; Henning Bünsow Boldt; Sune Munthe; Frantz Rom Poulsen; Bjarne Winther Kristensen
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

9.  MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis.

Authors:  Manjistha Sengupta; Bi-Dar Wang; Norman H Lee; Alexander Marx; Linda L Kusner; Henry J Kaminski
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

10.  MicroRNA‑718 serves a tumor‑suppressive role in non‑small cell lung cancer by directly targeting CCNB1.

Authors:  Shu Wang; Hongmei Sun; Xiaokai Zhan; Qiwen Wang
Journal:  Int J Mol Med       Date:  2019-11-04       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.